Catalent unveils OneBio Suite for biologics development

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/JK1991)
(Image: Getty/JK1991)

Related tags: Catalent, Biologics, BIO International Conference

Catalent is unveiling its OneBio Suite for the integrated development, manufacturing, and clinical supply of biologic drugs.

The company will announce the new suite during the BIO International Convention this week in Philadelphia, PA.

According to Catalent, OneBio was designed to address biologic development challenges by providing customers with a single contract, program manager, and development timeline.

“In OneBio, Catalent offers its partners the improved communications associated with streamlined program management and a single point of contact, reduced timelines brought about through parallel processing, and the increased flexibility of a global network of expertise and resources,”​ a Catalent spokesperson told us.

In early April, Catalent invested $5m​ in a new drug development center of excellence to expand its hot melt extrusion (HME) capabilities for formulation and drug delivery method optimization.

According to the company, the expansion enables Catalent to develop amorphous dispersions and controlled and modified drug delivery, such as controlled release for enhanced bioavailability.

Catalent also last month announced​ that it is installing new equipment to increase its formulation capabilities and capacity to manufacture controlled-release tablets and capsules.

The $40m investment will see the addition of a laser drill for osmotic drug delivery and stick pack dosage manufacturing capabilities at the company’s Winchester, KY-based facility.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars